Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin

International Journal of Oncology

Volumn 41, Issue 5, 2012, Pages 1762-1772

  Liu, Zhong Yan ^a   Qiu, Hai Ou ^a   Yuan, Xiao Jian ^a   Ni, Yan Yan ^a   Sun, Jian Jun ^a   Jing, Wei ^a   Fan, Yue Zu ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

3 Dimensional culture; Antilymphangiogenic therapy; Human lymphatic endothelial cell; Lymphangiogenesis; Norcantharidin

Indexed keywords

MATRIGEL; MESSENGER RNA; NORCANTHARIDIN; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3;

APOPTOSIS; ARTICLE; CANCER INVASION; CELL CULTURE; CELL LINE; CELL MIGRATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPE; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; TIME; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; ENDOTHELIUM, LYMPHATIC; GENE EXPRESSION REGULATION; HUMANS; LYMPHANGIOGENESIS; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84867796318     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1603     Document Type: Article

References (49)

1. Achen MG and Stacker SA: Tumor lymphangiogenesis and metastatic spread - new players begin to emerge. Int J Cancer 119: 1755-1760, 2006. (Pubitemid 44356830)
2. Nagahashi M, Ramachandran S, Rashid OM and Takabe K: Lymphangiogenesis: a new player in cancer progression. World J Gastroenterol 16: 4003-4012, 2010.
3. Tobler NE and Detmar M: Tumor and lymph node lymphangiogenesis- impact on cancer metastasis. J Leukoc Biol 80: 691-696, 2006. (Pubitemid 44835883)
4. Liersch R, Biermann C, Mesters RM and Berdel WE: Lymphangiogenesis in cancer: current perspectives. Recent Results Cancer Res 180: 115-135, 2010.
5. Sleeman JP and Thiele W: Tumor metastasis and the lymphatic vasculature. Int J Cancer 125: 2747-2756, 2009.
6. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG, Stacker SA and Alitalo K: Signaling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 20: 1223-1231, 2001. (Pubitemid 32233963)
7. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N and Alitalo K: Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 16: 3898-3911, 1997. (Pubitemid 27281006)
8. Siegfried G, Basak A, Cromlish JA, Benjannet S, Marcinkiewicz J, Chrétien M, Seidah NG and Khatib AM: The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest 111: 1723-1732, 2003. (Pubitemid 38057753)
9. Kowanetz M and Ferrara N: Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 12: 5018-5022, 2006. (Pubitemid 44453326)
10. Wissmann C and Detmar M: Pathways targeting tumor lymphangiogenesis. Clin Cancer Res 12: 6865-6868, 2006. (Pubitemid 44974477)
11. Ho YP, To KK, Au-Yeung SC, Wang X, Lin G and Han X: Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety. J Med Chem 44: 2065-2068, 2001. (Pubitemid 32861766)
12. Deng L and Tang S: Norcantharidin analogues: a patent review (2006-2010). Expert Opin Ther Pat 21: 1743-1753, 2011.
13. Fan YZ, Fu JY, Zhao ZM and Chen CQ: Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro. Hepatobiliary Pancreat Dis Int 6: 72-80, 2007.
14. Fan YZ, Zhao ZM, Fu JY, Chen CQ and Sun W: Norcantharidin inhibits growth of human gallbladder carcinoma xenografted tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo. Hepatobiliary Pancreat Dis Int 9: 414-422, 2010.
15. Chen YJ, Tsai YM, Kuo CD, Ku KL, Shie HS and Liao HF: Norcantharidin is a small-molecule synthetic compound with anti-angiogenesis effect. Life Sci 85: 642-651, 2009.
16. Zhang JT, Fan YZ, Chen CQ, Zhao ZM and Sun W: Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo. Int J Oncol 40: 1501-1514, 2012.
17. Achen MG and Stacker SA: Molecular control of lymphatic metastasis. Ann NY Acad Sci 1131: 225-234, 2008. (Pubitemid 351758517)
18. Zwaans BM and Bielenberg DR: Potential therapeutic strategies for lymphatic metastasis. Microvasc Res 74: 145-158, 2007. (Pubitemid 350051029)
19. Kotani M: The lymphatics and lymphoreticular tissues in relation to the action of sex hormones. Arch Histol Cytol 53 (Suppl): 1-76, 1990.
20. Zhang Z, Helman JI and Li LJ: Lymphangiogenesis, lymphatic endothelial cells and lymphatic metastasis in head and neck cancer - a review of mechanisms. Int J Oral Sci 2: 5-14, 2010.
21. Nathanson SD: Insights into the mechanisms of lymph node metastasis. Cancer 98: 413-423, 2003.
22. Hu J, Ye H, Fu A, Chen X, Wang Y, Chen X, Ye X, Xiao W, Duan X, Wei Y and Chen L: Deguelin - an inhibitor to tumor lymphangiogenesis and lymphatic metastasis by downregulation of vascular endothelial cell growth factor-D in lung tumor model. Int J Cancer 127: 2455-2466, 2010.
23. Dong X, Zhao X, Xiao T, Tian H and Yun C: Endostar, a recombined humanized endostatin, inhibits lymphangiogenesis and lymphatic metastasis of lewis lung carcinoma xenograft in mice. Thorac Cardiovasc Surg 59: 133-136, 2011.
24. Dong Z, Wei F, Zhou C, Sumida T, Hamakawa H, Hu Y and Liu S: Silencing Id-1 inhibits lymphangiogenesis through downregulation of VEGF-C in oral squamous cell carcinoma. Oral Oncol 47: 27-32, 2011.
25. Wen J, Fu AF, Chen LJ, Xie XJ, Yang GL, Chen XC, Wang YS, Li J, Chen P, Tang MH, Shao XM, Lu Y, Zhao X and Wei YQ: Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model. Int J Cancer 124: 2709-2718, 2009.
26. Pytowski B, Goldman J, Persaud K, Wu Y, Witte L, Hicklin DJ, Skobe M, Boardman KC and Swartz MA: Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst 97: 14-21, 2005.
27. Rinderknecht M, Villa A, Ballmer-Hofer K, Neri D and Detmar M: Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3. PLoS One 5: e11941, 2010.
28. Zhang D, Li B, Shi J, Zhao L, Zhang X, Wang C, Hou S, Qian W, Kou G, Wang H and Guo Y: Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein. Cancer Res 70: 2495-2503, 2010.
29. Lui Z, Ma Q, Wang X and Zhang Y: Inhibiting tumor growth of colorectal cancer by blocking the expression of vascular endothelial growth factor receptor 3 using interference vector-based RNA interference. Int J Mol Med 25: 59-64, 2010.
30. Yashiro M, Shinto O, Nakamura K, Tendo M, Matsuoka T, Matsuzaki T, Kaizaki R, Ohira M, Miwa A and Hirakawa K: Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model. Br J Cancer 101: 1100-1106, 2009.
31. Guo B, Zhang Y, Luo G, Li L and Zhang J: Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma. Anat Rec 292: 633-639, 2009.
32. Wang J, Zhang B, Guo Y, Li G, Xie Q, Zhu B, Gao J and Chen Z: Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C. Pharmacology 82: 148-155, 2008.
33. Iwata C, Kano MR, Komuro A, Oka M, Kiyono K, Johansson E, Morishita Y, Yashiro M, Hirakawa K, Kaminishi M and Miyazono K: Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res 67: 10181-10189, 2007. (Pubitemid 350070790)
34. Cao G, Wu JX and Wu QH: Low molecular weight heparin suppresses lymphatic endothelial cell proliferation induced by vascular endothelial growth factor C in vitro. Chin Med J 122: 1570-1574, 2009.
35. Nakamura ES, Koizumi K, Kobayashi M and Saiki I: Inhibition of lymphangiogenesis-related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproteinase inhibitor MMI270. Cancer Sci 95: 25-31, 2004. (Pubitemid 38208403)
36. Matsumoto G, Yajima N, Saito H, Nakagami H, Omi Y, Lee U and Kaneda Y: Cold shock domain protein A (CSDA) overexpression inhibits tumor growth and lymph node metastasis in a mouse model of squamous cell carcinoma. Clin Exp Metastasis 27: 539-547, 2010.
37. Ischenko I, Seeliger H, Camaj P, Kleespies A, Guba M, Eichhorn ME, Jauch KW and Bruns CJ: Src tyrosine kinase inhibition suppresses lymphangiogenesis in vitro and in vivo. Curr Cancer Drug Targets 10: 546-553, 2010.
38. An WW, Wang MW, Tashiro S, Onodera S and Ikejima T: Norcantharidin induces human melanoma A375-S2 cell apoptosis through mitochondrial and caspase pathways. J Korean Med Sci 19: 560-566, 2004. (Pubitemid 39194221)
39. Yi SN, Wass J, Vincent P and Iland H: Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro. Leuk Res 15: 883-886, 1991.
40. Yang PY, Chen MF, Tsai CH, Hu DN, Chang FR and Wu YC: Involvement of caspase and MAPK activities in norcantharidin-induced colorectal cancer cell apoptosis. Toxicol In Vitro 24: 766-775, 2010.
41. Chen YJ, Kuo CD, Tsai YM, Yu CC, Wang GS and Liao HF: Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells. Anticancer Drugs 19: 55-64, 2008.
42. McColl BK, Loughran SJ, Davydova N, Stacker SA and Achen MG: Mechanisms of lymphangiogenesis: targets for blocking the metastatic spread of cancer. Curr Cancer Drug Targets 5: 561-571, 2005. (Pubitemid 41789596)
43. Cohen-Kaplan V, Naroditsky I, Zetser A, Ilan N, Vlodavsky I and Doweck I: Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer 123: 2566-2573, 2008.
44. Hoshida T, Isaka N, Hagendoorn J, di Tomaso E, Chen YL, Pytowski B, Fukumura D, Padera TP and Jain RK: Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res 66: 8065-8075, 2006. (Pubitemid 44299172)
45. Bierer S, Herrmann E, Kopke T, Neumann J, Eltze E, Hertle L and Wülfing C: Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma. Oncol Rep 20: 721-725, 2008.
46. Choi JH, Oh YH, Park YW, Baik HK, Lee YY and Kim IS: Correlation of vascular endothelial growth factor-D expression and VEGFR-3-positive vessel density with lymph node metastasis in gastric carcinoma. J Korean Med Sci 23: 592-597, 2008.
47. Su JL, Yen CJ, Chen PS, Chuang SE, Hong CC, Kuo IH, Chen HY, Hung MC and Kuo ML: The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 96: 541-545, 2007.
48. Chen Z, Varney ML, Backora MW, Cowan K, Solheim JC, Talmadge JE and Singh RK: Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res 65: 9004-9011, 2005. (Pubitemid 41377392)
49. Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, Koprivnikar K, VanRoey MJ, He Y, Alitalo K and Jooss K: Inhibition of lymphogenous metastasis using adenoassociated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 65: 6901-6909, 2005. (Pubitemid 41060729)